Click here to go to the previous page
Innovative Strategies for Evolving Sponsor, CRO and Site Alliances
Program Code:
330
Date:
Wednesday, June 26, 2013
Time:
10:15 AM to 11:45 AM
EST
CHAIR
:
Mick O'Quigley,
MBA (SPKNON), Program Group Leader,
Genentech, A Member of the Roche Group, United States
Mick O'Quigley has over 20 years of drug development experience in the biopharmaceutical industry. Mick currently is a Program Group Leader in Clinical Operations at Genentech focusing on the development of early stage oncology molecules.
|
SPEAKER
(S):
Mick O''Quigley, MBA (SPKNON), Program Group Leader, Genentech, A Member of the Roche Group, United States
Lisa Marks, (SPKNON), Director, Business Development, PharmaSeek, United States
Michael Henning,
BSN,MBA (SPKNON), Director, Project Management,
PPD, United States
Michael Henning is a global director of project management within the hematology/oncology therapeutic area. He is responsible for operational management of key alliance accounts and the oversight of a portfolio of more than 30 studies across multiple therapeutic areas.
|
Description
The session will outline three perspectives on delivering improved outcomes using integrated alliance methodologies: the sponsor perspective on implementing a portfolio oversight committee to improve partnership alignment, integrated resourcing, early partnering and process improvements on an outsourced portfolio; the CRO perspective on building an integrated business unit by investing in the partnership; and the investigative site network perspective on bridging communication between site, CRO and sponsor.